Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity

Go back to Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity
Roche Holding AG Basel American Depositary Shares (AMEX: RHHBY) Delayed: 59.57 +0.46 (0.78%)
Previous Close $59.11    52 Week High $35.13 
Open $58.65    52 Week Low $28.10 
Day High $59.58    P/E N/A 
Day Low $58.41    EPS $0.00 
Volume 534,220